Monoallelic point mutations of isocitrate dehydrogenase type 1 (IDH1) are an early and
defining event in the development of a subgroup of gliomas,, and other types of tumour …

Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer
therapy by releasing the power of the immune system. However, only little is known about …

Background Although mutated HLA ligands are considered ideal cancer-specific
immunotherapy targets, evidence for their presentation is lacking in hepatocellular …

Our understanding of the antigen presentation pathway has recently been enhanced with
the identification that the tapasin-related protein TAPBPR is a second major …

Background & Aims We report a novel experimental immunotherapeutic approach in a
patient with metastatic intrahepatic cholangiocarcinoma. In the 5 year course of the disease …

Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with
poor prognosis despite surgical removal and radio-chemotherapy. In this setting …

Recently, we revealed that TAPBPR is a peptide exchange catalyst that is important for
optimal peptide selection by MHC class I molecules. Here, we asked whether any other co …

Background Atypical teratoid/rhabdoid tumors (AT/RT) are highly aggressive CNS tumors of
infancy and early childhood. Hallmark is the surprisingly simple genome with inactivating …

Abstract HLA-F adjacent transcript 10 (FAT10) is a cytokine-inducible ubiquitin-like modifier
that is highly expressed in the thymus and directly targets FAT10-conjugated proteins for …

Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to
immune escape in malignant disease. As a prerequisite for developing immunologic …